Trial Profile
MRD-guided Treatment With Pembrolizumab and Azacitidine in NPM1mut AML Patients With an Imminent Hematological Relapse
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Nov 2022
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Pembrolizumab (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms PEMAZA
- 11 Mar 2022 Planned End Date changed from 1 Aug 2022 to 1 Aug 2024.
- 11 Mar 2022 Planned primary completion date changed from 1 Aug 2021 to 1 Aug 2023.
- 29 Oct 2019 Status changed from not yet recruiting to recruiting.